I most recently played a key role in expanding market share of ischemic-related therapies in English-speaking Caribbean islands. ✔ Leveraging my background and expertise in the field, I developed a prevention project to educate physicians on identifying patients with high ischemic likelihood with a goal of lowering mortality rate with preventative diagnoses and treatment. ✔ Projections included 25% sales increase over next 2 years.Career Break Details► MANAGED PERM PROCESS… Show more I most recently played a key role in expanding market share of ischemic-related therapies in English-speaking Caribbean islands. ✔ Leveraging my background and expertise in the field, I developed a prevention project to educate physicians on identifying patients with high ischemic likelihood with a goal of lowering mortality rate with preventative diagnoses and treatment. ✔ Projections included 25% sales increase over next 2 years.Career Break Details► MANAGED PERM PROCESS FOR OBTAINING FAMILY’S PERMANENT RESIDENCE: 2014 – 2016► ENROLLED IN ADVANCED ENGLISH COURSES AT INLINGUA LANGUAGE CENTER AND TALK ACADEMY: 2014 – 2016► DIRECTED FAMILY MOVED FROM VENEZUELA TO UNITED STATES DUE TO RISING CIVIL UNREST AND COUNTRY CHALLENGES: August 2013 Show less

In Vargas Laboratory (from Vargas Corp), the aim was to develop a Marketing and Sales structure to reverse a continuous fall in sales and grow with new products, strategic alliances, and new markets penetration. ✔ I quickly implemented and directed a plan to reverse the decline and achieve positive growth. ✔ Under my guidance, we successfully reduced the loss of market share of -0.18% in 2010 and increased it positively to 0.04% in 2013. ✔ Additionally, there was a need for… Show more In Vargas Laboratory (from Vargas Corp), the aim was to develop a Marketing and Sales structure to reverse a continuous fall in sales and grow with new products, strategic alliances, and new markets penetration. ✔ I quickly implemented and directed a plan to reverse the decline and achieve positive growth. ✔ Under my guidance, we successfully reduced the loss of market share of -0.18% in 2010 and increased it positively to 0.04% in 2013. ✔ Additionally, there was a need for reassessing the commercial business in terms of which companies with whom we engaged to make our products. I managed an initiative that crafted, executed, and validated partnership procedures with international businesses; once launched, we were able to work out new prices and best service. My work here directly led to an increase in net income above 50%. Show less

✔ As General Pharma Director, I served as a leader and manager for Leti’s Pharmaceutical Business (83% of the total Corporation contribution margin). ✔ Additionally, I was fully responsible for the day- to-day running of various departments (Sales, Marketing, CRM, Marketing intelligence, Marketing multichannel, New Business and products, International License Partnership, KAM, etc) to ensure the teams’ smooth running. ✔ I also monitored the expected financial results and market share… Show more ✔ As General Pharma Director, I served as a leader and manager for Leti’s Pharmaceutical Business (83% of the total Corporation contribution margin). ✔ Additionally, I was fully responsible for the day- to-day running of various departments (Sales, Marketing, CRM, Marketing intelligence, Marketing multichannel, New Business and products, International License Partnership, KAM, etc) to ensure the teams’ smooth running. ✔ I also monitored the expected financial results and market share goals in addition to building up sales, marketing, and support teams across multiple divisions (530 collaborators, 9 directs) to promote 98+ pharma products, including 58 launches. ✔ As a result of the implementation of all these strategies, we could increase the US$ market share of Leti Pharmaceutical Ethical Division, from 2.98% in 2004 to 3.43% in 2010. Show less

The challenge was to rebuild the business of export to Central America and Peru, as well as develop new markets in the South American region. After implementing a series of successful strategies, unfortunately, we had to stop the project due to the implementation of the exchange control by the government in 2003. This limited fully the capacity of self-financing of the export business.

The main objective was the creation of independent OTC Business Units, supported by the commercial structure of J&J consumer and the structure of sales representatives by Janssen-Cilag. The product portfolio was comprised of products from both companies and McNeil acted as headquarters. The countries chosen were Mexico, Argentina, Brazil, and Venezuela, forming a network of a continuous exchange of strategies and procedures among all. ✔ My responsibilities were the creation and development… Show more The main objective was the creation of independent OTC Business Units, supported by the commercial structure of J&J consumer and the structure of sales representatives by Janssen-Cilag. The product portfolio was comprised of products from both companies and McNeil acted as headquarters. The countries chosen were Mexico, Argentina, Brazil, and Venezuela, forming a network of a continuous exchange of strategies and procedures among all. ✔ My responsibilities were the creation and development of the Venezuelan OTC Division; evaluation of the business potential; financial and market share goals. ✔ We developed and implemented successful strategies for obtaining prescriptions from doctor target and for the sellers of J&J consumer. This strategy helped us to increase the inter-annual sales in 15 % average. ✔ Additionally, the launch of Tylenol proved a great success both prescriptive (infant Tylenol became the most prescribed product in its class), overcoming the expectations in 35 % average. Show less

After 10 years of experience in transnational American companies, a very interesting project emerged in a National company. ✔ The ultimate aim of this project was to start the private medical promotion of the Calox products since it is only advertised in hospitals and pharmacies. Secondly, we wanted to modernize the portfolio of products with the development of new molecules selected by marketing. ✔ All of this contributed to achieving sale increases over 25 % inter-annual. ✔… Show more After 10 years of experience in transnational American companies, a very interesting project emerged in a National company. ✔ The ultimate aim of this project was to start the private medical promotion of the Calox products since it is only advertised in hospitals and pharmacies. Secondly, we wanted to modernize the portfolio of products with the development of new molecules selected by marketing. ✔ All of this contributed to achieving sale increases over 25 % inter-annual. ✔ Additionally, there was a desire to internationalize the pharmaceutical business mainly toward Central America region. In this project, I had the responsibility of representing the company towards a successful transition. Show less

Charged with creative and innovative marketing plans and strategies in an effort to change the negative trend in its performance. Responsible for Marketing and Sales team performance, Market Share, Sales goals and Marketing Contribution at P&L level. ✔ I led a successful reorientation of the Nutritional business. ✔ Additionally, I managed the development and implementation of the new OTC business project. It represented the beginning of a new experience for me because as it was the… Show more Charged with creative and innovative marketing plans and strategies in an effort to change the negative trend in its performance. Responsible for Marketing and Sales team performance, Market Share, Sales goals and Marketing Contribution at P&L level. ✔ I led a successful reorientation of the Nutritional business. ✔ Additionally, I managed the development and implementation of the new OTC business project. It represented the beginning of a new experience for me because as it was the first time I had the opportunity to handle both marketing and sales Show less

Started career as Sales Rep. at Merck Co.; quickly promoted to Marketing Coordinator before switching to Schering Plough as Product Manager. Then moved to Bristol Myers Squibb as a Pharmaceutical Marketing Manager. 1985-1993